Expert Outlook: Praxis Precision Medicine Through The Eyes Of 5 Analysts

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Praxis Precision Medicine PRAX in the last three months.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $145.8, a high estimate of $175.00, and a low estimate of $120.00. This current average has increased by 6.58% from the previous average price target of $136.80.

Exploring Analyst Ratings: An In-Depth Overview

In examining recent analyst actions, we gain insights into how financial experts perceive Praxis Precision Medicine. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Praxis Precision Medicine. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Praxis Precision Medicine compared to the broader market.
• Price Targets: Analysts predict movements in price targets, offering estimates for Praxis Precision Medicine's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Praxis Precision Medicine's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Praxis Precision Medicine analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Praxis Precision Medicine: A Closer Look

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.

Praxis Precision Medicine: Delving into Financials

Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.

Negative Revenue Trend: Examining Praxis Precision Medicine's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -35.47% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Praxis Precision Medicine's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -17188.74%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Praxis Precision Medicine's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -12.95%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Praxis Precision Medicine's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -12.11%, the company may face hurdles in achieving optimal financial returns.

Debt Management: With a below-average debt-to-equity ratio of 0.0, Praxis Precision Medicine adopts a prudent financial strategy, indicating a balanced approach to debt management.

Analyst Ratings: Simplified

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.